Clinical Trial Update: Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ixazomib-pomalidomide-dexamethasone as second or third-line treatment for relapsed and refractory multiple myeloma after prior daratumu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• NINLARO (ixazomib)
• Pomalyst (pomalidomide)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING